Financial Preferred Invesco ETF (PGF)
$18.77 0.05 (0.27%)
20:00 EDT PGF Stock Quote Delayed 30 Minutes
Previous Close $18.77
Market Cap 1.60B
PE Ratio -
Volume (Avg. Vol.) 324,600
Day's Range 18.74 - 18.87
52-Week Range 12.30 - 19.15
Dividend & Yield 0.91 (4.85%)
PGF Stock Predictions, Articles, and Financial Preferred Invesco ETF News
- From InvestorPlace
- From the Web
The stock market bulls are playing hide and seek as the Dow Jones Industrial Average has been trading in wild swings this week. Compare Brokers...
Exchange-traded funds (ETFs) and low taxes go a hand in hand. Here are three of the best ETFs to buy to keep the tax man at bay.
A half-million dollars is a lot of money. It can last for you, but you need to look carefully into these instruments to help in your planning
From The Motley Fool
From Seeking Alpha
Amid concerns among Americans that the rush to approve COVID-19 vaccines may lead to corner-cutting and end products that are not up to typical FDA efficacy standards, leading developers Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) have taken the unusual steps of publishing the protocols of the large-scale late-stage trials for their respective candidates.Moderna's Phase 3 trial of mRNA-1273, two 100 microgram doses 28 days apart, will recruit ~30K adults, 60-75% younger than 65 years old not at risk for complications and 25-40% at least 65 years old (the single most significant risk factor) or less than 65 at increased risk of COVID-19 complications.The primary efficacy endpoint is the incidence of first-occurrence COVID-19 cases starting 14 days after the second shot.A confirmed (via molecular test) COVID-19 case is defined as a participant who has experienced at least TWO of the following symptoms: fever (≥ 38ºC), chills, myalgia (muscle soreness), headache, sore throat, new olfactory and taste disorder(s) OR he/she must have experienced at least ONE of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing OR clinical or radiographic evidence of pneumonia.Pfizer and BioNTech's (NASDAQ:BNTX) Phase 3 study of BNT162b2, two 30 microgram doses 21 days apart, will recruit 30K adults stratified in two groups: 16-55 years old and 55+.The primary efficacy endpoint is the incidence of confirmed COVID-19 cases starting 7 days after the second shot as measured by the number of cases per 1,000 person-years of follow-up.A confirmed (via molecular test) COVID-19 case is defined as participants experiencing at least ONE of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased myalgia (muscle soreness), new loss of taste or smell, sore throat, diarrhea or vomiting.Moderna's criteria are a more restrictive and could potentially show a higher efficacy rate for mRNA-1273 as a result.The number of COVID-19 cases in people who just reported one symptom is unknown.
From Market News Video